Journals / Romatizma Dergisi / 2006 / Cilt: 21 - Sayı: 1

The role of disease activity in the determination of functional status and quality of life in patients with ankylosing spondylitis

Ankilozan spondilit'li olgularda, hastalık aktivitesinin fonksiyonel durum ve yaşam kalitesini belirlemediki rolü

Pages
9–12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: These results show that the cut off level of BASDAI≥4 choosen for determination of disease activity is discriminatory for functional status but not for quality of life.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Disease activity in patients with AS is evaluated with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
📊
Key Findings & Data:BASDAI≥4 is accepted as active disease.
💡
Conclusion & Impact:Conclusion: These results show that the cut off level of BASDAI≥4 choosen for determination of disease activity is discriminatory for functional status but not for quality of life.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Spondilit · ankilozan · Yaşam kalitesi

Abstract

Objective: Disease activity in patients with AS is evaluated with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). BASDAI&#8805;4 is accepted as active disease. The effect of disease activity on functional status and quality of life was investigated in this study. Patients and Methods: 37 patients who fulfilled the modified New York criteria for AS were included in this study. The patients were divided into two groups; group 1 (BASDAI<4) and group 2 (BASDAI&#8805;4). Functional status [Bath Ankylosing Spondylitis Functional Index (BASFI)], physical stiffness [Health Assessment Question naire-Spondyloarthropathy (HAQ-S)] and quality of life [Ankylosing Spondylitis Quality of Life (ASQoL)] were evaluated in order to compare the groups. Results: There were 17 patients in group 1 (M/F= 16/1) and 20 patients in group 2 (M/F= 14/6). The mean of ages and disease duration were 38.1±12.4 year and 102.7±88.0 months in group 1 and 39.3±9.7 year and 98.6±74.6 months in group 2 (p=0.762, 0.879 respectively). Patients with a BASDAI &#8805;4 had a worse functional status evaluated with HAQ-S and BASFI than those who have a BASDAI of <4 (p=0.000). However there was no difference in respect to the level of quality of life between the groups (p=0.461). Conclusion: These results show that the cut off level of BASDAI&#8805;4 choosen for determination of disease activity is discriminatory for functional status but not for quality of life.

Özet

Amaç: Ankilozan spondilitli (AS) olgularda hastalık aktivitesi Bath Ankilozan Spondilit Hastalık Aktivite İndeksi (BASDAI) ile değerlendirilir. BASDAI ≥4 olması aktif hastalık olarak kabul edilir. Bu çalışmada hastalık aktivitesinin fonksiyonel durum ve yaşam kalitesine etkisi araştırıldı. Hastalar ve Yöntem: Çalışmaya 1984 modifiye New York kriterlerine göre kesin AS tanısı almış 37 hasta alındı. Hastalar BASDAI<4 (grup 1) ve BASDAI≥4 (grup 2) olanlar olmak üzere iki gruba ayrıldı. İki grup fonksiyonel durum [Bath Ankilozan Spondilit Fonksiyonel İndeksi (BASFI)], fiziksel kısıtlılık [Sağlık Değerlendirme Anketi-Spondilartropati (HAQ-S)] ve yaşam kalitesi [AS Yaşam Kalitesi (ASQoL)] bakımından karşılaştırıldı. Bulgular: Grup 1'de 17 (E/K= 16/1), grup 2'de 20 (E/K= 14/6) hasta yer aldı. Grup 1 ve 2'nin yaş ort. ve ortalama hastalık süresi sırasıyla 38.1±12.4 yıl, 102.7±88.0 ay; 39.3±9.7 yıl, 98.6±74.6 ay idi (sırasıyla p=0.762, 0.879). BASDAI≥4 olan hastaların HAQ-S ve BASFI ile değerlendirilen fonksiyonel durumu BASDAI<4 olanlara göre daha kötü idi (p=0.000). Ancak yaşam kalitesi düzeyi bakımından iki grup arasında fark bulunmadı (p=0.461). Sonuç: Bu bulgular, hastalık aktivitesini belirlemek için seçilmiş bu eşik düzeyin fonksiyonel durum için de belirleyici olduğunu ancak yaşam kalitesi konusunda ayırt ettirici olmadığını göstermiştir.

🔖

Cite This Article

KAYA, T., KARATEPE, G. A., GÜNAYDIN, R., ÜRPER, S. (2006). The role of disease activity in the determination of functional status and quality of life in patients with ankylosing spondylitis. Romatizma Dergisi, Cilt: 21 - Sayı: 1, 9–12. https://ajindex.com/articles/306211

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Özgül A, Peker F, Taşkaynatan MA, et al. Effect of Ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients. Clin Rheumatol 2006; 25: 168-74
  2. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817-24
  3. Garret S, Jenkinson T, Kennedy L, et al. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91
  4. Calin A, Garret S, Whitelock H, et al. A new approach to defining functional ability in Ankylosing Spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5
  5. Daltroy LH, Larson MG, Roberts WN, et al. A modification of the Health Assessment Questionnaire for the spondylarthropathies. J Rheumatol 1990;17: 946-50
  6. Barkham N, Kong KO, Tennant A, et al. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatol 2005; 44: 1277-81
  7. Burgos-Vargas R, Rojas-Serrano J. Predictors of response to tumour necrosis factor-a blockers in ankylosing spondylitis. J Rheumatol 2005; 32: 1637-40
  8. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor a (TNF a) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005; 64(Suppl4): iv2-iv14
  9. Ledingham J, Deighton C. On behalf of the British Society for Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005; 44:157-63
  10. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62:817-24
  11. Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument spesific to ankylosing spondylitis. Ann Rheum Dis 2003; 62: 20-6
  12. Cella D, Nowinsky CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 2002; 83(Suppl 2): S10-S17